2022--provirex--hamburg-researchers-want-to-be-able-to-cure-hiv-soon---magazine--healty-and-sport-news May 2026

Research published in Nature Biotechnology demonstrated that Brec1 can target and excise over 90% of clinical HIV-1 isolates found globally.

The core of Hamburg’s research is , developed through directed molecular evolution by teams led by Prof. Joachim Hauber. Building upon the research conducted by and the

Building upon the research conducted by and the University Medical Center Hamburg-Eppendorf (UKE) , this paper outlines the scientific and strategic progress made toward a functional HIV cure as of late 2022. Abstract The Challenge: Beyond Viral Suppression

In October 2022, PROVIREX announced a major expansion in Hamburg’s . " the underlying Brec1 technology

In 2022, Hamburg emerged as a primary hub for curative HIV research following significant investment in , a biotech startup utilizing "designer recombinase" technology. Unlike traditional antiretroviral therapy (ART) which only suppresses viral replication, the Brec1 recombinase acts as a molecular scalpel to precisely excise integrated HIV-1 DNA from the host genome. This paper details the 2022 expansion of Hamburg’s "Therapy Hub," the underlying Brec1 technology, and the transition toward Phase Ib/IIa clinical trials. 1. The Challenge: Beyond Viral Suppression